Nihat KALAY, Mustafa YAŞAN, Ferhan ELMALI, Ömer ŞAHİN, Abdurrahman OĞUZHAN, Göktuğ SAVAŞ, Uğur KARABIYIK, Ali DOĞAN

Does the v Does the volume o olume overload exagger erload exaggerate the se ate the severity of mitr erity of mitral regurgitation in patients with decompensated heart failure?

Background/aim: Diagnosing and managing functional mitral regurgitation (MR) is often challenging and requires an integrated approach including a comprehensive echocardiographic examination. However, the effects of volume overload on the echocardiographic assessment of MR severity are uncertain. The purpose of this study was to weigh the effects of volume overload in the echocardiographic assessment of MR severity among patients with heart failure (HF). Materials and methods: Twenty-nine patients with decompensated HF, who had moderate or severe MR, were included in the present study. The volume status and the N-terminal pro-B-type natriuretic peptide (proBNP) levels were recorded and the echocardiographic parameters were assessed. After the conventional treatment for HF, the proBNP levels and the echocardiographic parameters were assessed again. Results: The mean age of the patients was 72 ± 9 years and the average hospitalization time was 10.9 ± 5.9 days. Between the beginning and the end of the treatment, there were significant reductions in the effective regurgitant orifice area (EROA) (0.36 ± 0.09 cm2 to 0.29 ± 0.09 cm2 , P < 0.001), vena contracta (VC) (P < 0.001), the regurgitant volume (RV) (P < 0.001), and systolic pulmonary artery pressure (sPAP) (P < 0.001). Conclusion: This is the first study to investigate the relationship of changes in severity of MR with volume-load by monitoring the proBNP levels among patients with HF. The present results demonstrated that volume reduction, as evidenced by a decline in the proBNP levels, was accompanied by a marked reduction in the EROA, VC, and the RV among patients with left ventricular dysfunction.

PDF

___

1. Carabello BA. The current therapy for mitral regurgitation. Journal of the American College of Cardiology 2008; 52 (5): 319-326. doi: 10.1016/j.jacc.2008.02.084
2. Trichon BH, Felker GM, Shaw LK, Cabell CH, O’Connor CM. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. American Journal of Cardiology 2003; 91 (5): 538-543. doi: 10.1016/s0002-9149(02)03301-5
3. Baumgartner H, Falk V, Bax JJ, Bonis MD, Hamm C et al. ESC Scientific Document Group: 2017 ESC/EACTS guidelines for the management of valvular heart disease. European Heart Journal 2017; 38 (36): 2739-2791. doi: 10.1093/eurheartj/ ehx391
4. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on clinical practice guidelines. Journal of the American College of Cardiology 2017; 70 (2): 252-289. doi: 10.1016/j.jacc.2017.03.011
5. Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. Journal of the American College of Cardiology 2015; 65 (12): 1231-1248. doi: 10.1016/j.jacc.2015.02.009
6. Thavendiranathan P, Phelan D, Collier P, Thomas JD, Flamm SD et al. Quantitative assessment of mitral regurgitation: how best to do it. Journal of the American College of Cardiology Cardiovascular Imaging 2012; 5 (11): 1161-1175. doi: 10.1016/j. jcmg.2012.07.013
7. Yoran C, Yellin EL, Becker RM, Gabbay S, Frater RW et al. Dynamic aspects of acute mitral regurgitation: effects of ventricular volume, pressure and contractility on the effective regurgitant orifice area. Circulation 1979; 60 (1): 170-176. doi: 10.1161/01.cir.60.1.170
8. Shiota T, Jones M, Teien DE, Yamada I, Passafini A et al. Dynamic change in mitral regurgitant orifice area: comparison of color Doppler echocardiographic and electromagnetic flowmeter-based methods in a chronic animal model. Journal of the American College of Cardiology 1995; 26 (2): 528-536. doi: 10.1016/0735-1097(95)80033-d
9. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. New England Journal of Medicine 1998; 339 (5): 321-328. doi: 10.1056/NEJM199807303390507
10. Pizarro R, Bazzino OO, Oberti PF, Falconi M, Achilli F et al. Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. Journal of the American College of Cardiology 2009; 54 (12): 1099-1106. doi: 10.1016/j. jacc.2009.06.013
11. Baig MK, Mahon N, McKenna WJ, Caforio AL, Bonow RO et al. The pathophysiology of advanced heart failure. Heart Lung 1999; 28 (2): 87-101. doi: 10.1053/hl.1999.v28.a97762
12. Yamanouchi S, Kudo D, Endo T, Kitano Y, Shinozawa Y. Blood N-terminal ProBNP as a potential indicator of cardiac preload in patients with high volume load. Tohoku Journal of Experimental Medicine 2010; 221 (3): 175-180. doi: 10.1620/ tjem.221.175
13. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging 2015; 16 (3): 233-270. doi: 10.1093/ ehjci/jev014
14. Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E et al. Recommendations for noninvasive evaluation of native valvular regurgitation: A report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. Journal of the American Society of Echocardiography 2017; 30 (4): 303-371. doi: 10.1016/j.echo.2017.01.007
15. Gök G, Çınar T, Sayar N. Quantification of rheumatic mitral stenosis severity with three-dimensional vena contracta area. Echocardiography 2019; 36 (2): 370-375. doi: 10.1111/ echo.14213
16. Grayburn PA. How to measure severity of mitral regurgitation: valvular heart disease. Heart 2008; 94 (3): 376-383. doi: 10.1136/hrt.2005.086462
17. Keren G, Katz S, Strom J, Sonnenblick EH, LeJemtel TH. Dynamic mitral regurgitation. An important determinant of the hemodynamic response to load alterations and inotropic therapy in severe heart failure. Circulation 1989; 80 (2): 306- 313. doi: 10.1161/01.cir.80.2.306
18. Keren G, Bier A, Strom JA, Laniado S, Sonnenblick EH et al. Dynamics of mitral regurgitation during nitroglycerin therapy: a Doppler echocardiographic study. American Heart Journal 1986; 112 (3): 517-525. doi: 10.1016/0002-8703(86)90516-8
19. Capomolla S, Pozzoli M, Opasich C, Febo O, Riccardi G. Dobutamine and nitroprusside infusion in patients with severe congestive heart failure: hemodynamic improvement by discordant effects on mitral regurgitation, left atrial function, and ventricular function. American Heart Journal 1997; 134 (6): 1089-1098. doi: 10.1016/s0002-8703(97)70030-9
20. Wilcox J, Yancy CW. Stopping medication for heart failure with improved ejection fraction. Lancet 2019; 393 (10166): 8-10. doi: 10.1016/S0140-6736(18)32825-3
21. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. New England Journal of Medicine 2002; 346 (18): 1357-1365. doi: 10.1056/NEJMoa012630
22. Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A et al. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. Journal of the American College of Cardiology 2011; 57 (13): 1468-1476. doi: 10.1016/j. jacc.2010.11.030
23. Maurer MS, Sackner-Bernstein JD, El-Khoury Rumbarger L, Yushak M, King DL et al. Mechanisms underlying improvements in ejection fraction with carvedilol in heart failure. Circulation Heart Failure 2009; 2 (3): 189-196. doi: 10.1161/CIRCHEARTFAILURE.108.806240
24. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ et al. Long-term trends in the incidence of and survival with heart failure. New England Journal of Medicine 2002; 347 (18): 1397- 1402. doi: 10.1056/NEJMoa020265
25. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG et al. Burden of valvular heart diseases: a population-based study. Lancet 2006; 368 (9540): 1005-1011. doi: 10.1016/S0140- 6736(06)69208-8
26. Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ et al. Percutaneous repair or surgery for mitral regurgitation. New England Journal of Medicine 2011; 364 (15): 1395-1406. doi: 10.1056/NEJMoa1009355
27. Armeni P, Boscolo PR, Tarricone R, Capodanno D, Maggioni AP et al. Real-world cost effectiveness of MitraClip combined with medical therapy versus medical therapy alone in patients with moderate or severe mitral regurgitation. International Journal of Cardiology 2016; 209: 153-160. doi: 10.1016/j. ijcard.2016.01.21